PureTech Health Plc (PRTC)
17.42
0.00 (0.00%)
Upcoming Events
Latest Headlines
PureTech Health: Results of Annual General Meeting
June 10, 2026 1:14 PM - BizWire
Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug
June 9, 2026 2:00 AM - StreetInsider
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
June 9, 2026 2:00 AM - BizWire
Form F-6 POS PureTech Health plc Filed by: Citibank,N.A./ADR
May 22, 2026 12:22 PM - SEC Filing
Form 424B3 PureTech Health plc
May 21, 2026 10:32 AM - SEC Filing
Form 15F-12B PureTech Health plc
May 21, 2026 8:32 AM - SEC Filing
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
May 13, 2026 7:00 AM - BizWire
Form 25 PureTech Health plc
May 11, 2026 4:06 PM - SEC Filing
Form SCHEDULE 13G/A PureTech Health plc Filed by: CITIGROUP INC
May 11, 2026 3:05 PM - SEC Filing
Form 6-K PureTech Health plc For: May 01
May 1, 2026 11:51 AM - SEC Filing
Form SCHEDULE 13G PureTech Health plc Filed by: TANG CAPITAL MANAGEMENT LLC
April 29, 2026 4:17 PM - SEC Filing
Form 20-F PureTech Health plc For: Dec 31
April 29, 2026 10:49 AM - SEC Filing
Form 6-K PureTech Health plc For: Apr 29
April 29, 2026 6:11 AM - SEC Filing
Form 6-K PureTech Health plc For: Apr 29
April 29, 2026 6:10 AM - SEC Filing
PureTech plans to delist from NASDAQ, focus trading on London exchange
April 29, 2026 5:53 AM - StreetInsider
PureTech Announces Annual Results for Year Ended December 31, 2025
April 29, 2026 2:01 AM - BizWire
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
April 29, 2026 2:00 AM - BizWire
Seaport Therapeutics appoints Dr. Sharon Mates to board of directors
April 27, 2026 7:05 AM - StreetInsider
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
April 27, 2026 7:05 AM - BizWire
PureTech reports positive data from cancer drug trial
April 22, 2026 7:00 AM - StreetInsider
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
April 22, 2026 7:00 AM - BizWire
PureTech Health: Notice of Results
April 13, 2026 2:05 AM - BizWire
PureTech publishes phase 2b trial results for lung fibrosis drug
April 2, 2026 8:19 AM - StreetInsider
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
April 2, 2026 8:19 AM - BizWire
Seaport Therapeutics reports positive phase 1 results for anxiety drug
April 2, 2026 7:08 AM - StreetInsider
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
April 2, 2026 7:08 AM - BizWire
Seaport Therapeutics publishes data on oral allopregnanolone prodrug
March 25, 2026 2:05 PM - StreetInsider
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutical
March 25, 2026 2:04 PM - BizWire
Full Article List
